Acurian Expands Specialized Consumer Marketing Group to Meet Increased Demand for Clinical Trial Patients

HORSHAM, Pa.--(BUSINESS WIRE)--Acurian, Inc., a leading, full-service provider of global patient enrollment and retention solutions, announced today that it has doubled its consumer marketing group in response to record levels of customer demand for trial participants and an all-time high in project backlog.

“No other company in our space has the firepower and internal expertise when it comes to identifying and contacting potential clinical trial participants in specific site geographies worldwide”

The consumer marketing group, which has grown from six to 12 full-time employees, is dedicated to enhancing Acurian’s wide-ranging and proven recruitment capabilities in direct mail, TV, radio, print, and online, while developing new strategies to cost-effectively reach people who live close, but are otherwise unknown to, research sites.

Led by Erica Prowisor, Senior Director of Global Consumer Marketing, the expanded department functions as an in-house resource to provide sponsors with enrollment strategies and tactics underscored by unparalleled efficiencies in campaign development, launch, pricing, and quality control.

“No other company in our space has the firepower and internal expertise when it comes to identifying and contacting potential clinical trial participants in specific site geographies worldwide,” stated Prowisor. “In fact, the size of our consumer marketing department is larger than most patient recruitment agencies and certainly larger than most patient recruitment groups within CROs. With all of these resources maintained and managed on site, we can consistently deliver randomized patients more predictably, faster and cost-effectively than any other provider.”

As the recognized global specialist, Acurian is routinely contracted to provide 30 to 60% of all randomized patients for industry-sponsored, U.S. and international late-phase trials. The company’s contribution ranges from relatively small numbers of trial participants to over 4,000 randomized patients.

Rick Malcolm, Acurian’s CEO, reiterated that Acurian’s investment in expanding the size and capabilities of its consumer marketing group reflects the growing number and scope of projects under contract. “Sponsors are asking us to provide more patients per project than ever before, both domestically and abroad. We are making sure that we can deliver on patient volume under intense deadlines, especially as sites and CROs are increasingly challenged to do so.”

About Acurian

Acurian is a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening, and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites, time, or CRO change orders. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures.